Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”
Overview
Archive, CME credit no longer available
Release Date: April 10, 2006
Expiration Date: April 10, 2007
This activity consists of audio and visual recording of 9 live presentations.
To view presentation, the learner should click on a presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he/she chooses. Learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.
Needs and Objectives
Upon completion of this activity, learners will be able to:
- Formulate appropriate management strategies unique to HIV and hepatitis B virus and hepatitis C virus coinfections
- Identify treatment strategies to manage liver complications and hepatotoxicity in HIV disease
- Design antiretroviral strategies that consider
- The risks of drug-drug interactions among antiretrovirals and other common medications
- The role of the nRTI class in antiretroviral regimens
- Issues unique to the antiretroviral treatment-naive patient
- The potential role of new and emerging antiretroviral drugs in antiretroviral therapy, especially in antiretroviral failure
- Describe the current developments in HIV prevention in the clinical care setting
- Design treatment strategies for metabolic complications of antiretroviral therapy and related primary care issues
Intended Audience
This online CME activity is designed for physicians who are actively involved in HIV/AIDS care. Specifically, these activities have been designed for physicians who:
- Have a solid, working knowledge of HIV disease management
- Provide comprehensive or specialty care for at least 10 patients with HIV/AIDS or are involved in HIV/AIDS clinical trials or investigations
- Have completed at least 10 hours of CME in the area of HIV/AIDS medicine in the past 2 years
This activity is also relevant to nurse practitioners, physician assistants, nurses, and other health professionals who provide care to people with HIV disease.
Course Faculty
Chairs
Gerald H. Friedland, MD
Course Chair
Professor of Medicine, Epidemiology, and Public Health
Yale University School of Medicine
Director, AIDS Care Program
Yale-New Haven Hospital
New Haven, Connecticut
Paul A. Volberding, MD
Course Vice-Chair
Founding Board Chair
International AIDS Society–USA
Professor of Medicine
Vice-Chair, Department of Medicine
University of California San Francisco
Chief of Medical Service
San Francisco Veterans Affairs Medical Center
San Francisco, California
Speakers
Judith A. Aberg, MD
Associate Professor of Medicine
New York University
Director of HIV Services
Bellevue Hospital Center
Principal Investigator
AIDS Clinical Trials Unit
New York, New York
David J. Back, PhD
Professor of Pharmacology
University of Liverpool
Liverpool, United Kingdom
Raymond T. Chung, MD
Assistant Professor of Medicine
Harvard Medical School
Director of Hepatology
Massachusetts General Hospital
Boston, Massachusetts
Myron S. Cohen, MD
J Herbert Bate Professor of Medicine, Microbiology, and Public Health
Director, Division of Infectious Diseases
Director, University of North Carolina Center
for Infectious Diseases
The University of North Carolina
at Chapel Hill
Chapel Hill, North Carolina
Roy M. Gulick, MD, MPH
Member, Board of Directors
International AIDS Society–USA
Associate Professor of Medicine
Division of International Medicine and Infectious Diseases
Director, Cornell Clinical Trials Unit
Weill Medical College of Cornell University
New York, New York
Scott M. Hammer, MD
Professor of Medicine
Columbia University College of Physicians
and Surgeons
Chief, Division of Infectious Disease
Columbia Presbyterian Medical Center
New York, New York
Michael S. Saag, MD
Member, Board of Directors
International AIDS Society–USA
Professor of Medicine
Director, Center for AIDS Research
The University of Alabama at Birmingham
Birmingham, Alabama
Kenneth E. Sherman, MD, PhD
Gould Professor of Medicine
Director, Division of Digestive Diseases
University of Cincinnati College of Medicine
Cincinnati, Ohio
Disclosure of Financial Affiliations
In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the International AIDS Society-USA requires all persons with control of content (ie; faculty, IAS-USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any conflicts of interest of those parties are resolved prior to the education activity being delivered.
IAS-USA Board of Directors
Constance A. Benson, MD
Dr Benson received research support from or served as a consultant to Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, and Pfizer. She had stock options for Monogram Biosciences and Vertex. (Updated 03/21/07)
Judith S. Currier, MD
Dr Currier received grants and research support from and served as a consultant to Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, and Tibotec. (Updated 03/12/07)
Carlos del Rio, MD
Dr del Rio received grants and research support from GlaxoSmithKline, Merck, and Pfizer. He served as a consultant or was on the speakers’ bureau of Abbott, Merck, and Roche. (Updated 10/09/06)
Joel E. Gallant, MD, MPH
Dr Gallant received grants and research support from Gilead, GlaxoSmithKline, Merck, Pfizer, Roche, and Tibotec, and honoraria from Abbott, Gilead, GlaxoSmithKline, Monogram Biosciences, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Koronis, Merck, Monogram Sciences, Panacos, Pfizer, Schering Plough, Tibotec, and Vertex. (Updated 10/09/07)
Roy M. Gulick, MD, MPH
Dr Gulick received research grants from Gilead, Merck, Panacos, Pfizer, Schering, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Pfizer, Roche-Trimeris, Schering, Tibotec, and Virco. (Updated 03/05/07)
Donna M. Jacobsen
Ms Jacobsen had no relevant financial affiliations to disclose. (Updated 03/22/07)
Douglas D. Richman, MD
Dr Richman served as a consultant to Achillion, Anadys, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Idinex, Merck, Monogram, Pfizer, Roche, and Tibotec. (Updated 10/09/06)
Michael S. Saag, MD
Dr Saag received grants and research support from Achillion Pharmaceuticals, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Panacos, Pfizer, Progenics, Roche, Serono, Tibotec, Trimeris, and Vertex. He served as a scientific advisor to Achillion, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Panacos, Pfizer, Progenics, Roche, Tanox, Tibotec/Virco, Trimeris, and Vertex. (Updated 03/22/07)
Robert T. Schooley, MD
Dr Schooley received and research support and honoraria from or served as a consultant to Abbott, Anadys, Anormed, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Pfizer, Roche, Schering-Plough, Tanox, Tibotec and Vertex. (05/16/07)
Paul A. Volberding, MD
Dr Volberding served on the advisory boards for Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Pfizer, and Schering, and was on the endpoint adjudication committee of Schering. He received honoraria for speaking from Bristol-Myers Squibb, Gilead, and Vertex. He had stock options for Immune Response Corporation. (Updated 01/22/07)
Course Faculty and Staff
Below are the disclosures of financial relationships of the faculty and program staff of this Web-based CME conference.
Dr Aberg has received grants and research support from Berlex, Bristol-Myers Squibb, Gilead, Merck, and Pfizer. She has also served as a scientific advisor to Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, and GlaxoSmithKline. She is on the speakers’ bureau of Boehringer Ingelheim.
Dr Back has received grants and research support from Abbott, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Roche, and Tibotec. He has also served as a consultant to or is on the speakers’ bureau of Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, and GlaxoSmithKline.
Dr Chung has received grants and research support from Roche and Schering.
Dr Cohen has served as a scientific advisor for GlaxoSmithKline.
Dr Friedland has received grants and research support from Abbott and Boehringer Ingelheim.
Dr Gulick has received research grant support from Abbott, Boehringer Ingelheim, Merck, Pfizer, Serono, Schering, and Tibotec. He has also served as a scientific advisor or consultant to Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Pfizer, and Tibotec. He has received speaker honoraria from Gilead and Monogram Biosciences.
Dr Hammer has received grants and research support from Merck. He has served as a scientific advisor to Boehringer Ingelheim, Progenics, Pfizer, and Tibotec-Virco.
Dr Saag has received grants and research support from Gilead, GlaxoSmithKline, Panacos, Pfizer/Agouron, Roche, Serono, and Tibotec. He has served as a scientific advisor to Achillion, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Monogram Biosciences, Panacos, Pfizer/Agouron, Progenics, Roche, Tanox, Tibotec/Virco, Trimeris, and Vertex.
Dr Sherman has received grants and research support from Idenix, Roche, and Schering. He has also served as a consultant to Proctor & Gamble and SciClone, and is on the speakers’ bureau of Abbott, Roche, and Schering.
Dr Volberding has served on the advisory boards for Bristol-Myers Squibb, Merck, and Pfizer, and is on the Data Safety Monitoring Boards of Incyte and Schering. He has received honoraria from Bristol.
IAS–USA CME Staff
Ms Jacobsen has no relevant financial affiliations to disclose.
Ms Wilson has no relevant financial affiliations to disclose.
Grant Support
This Webcast activity is sponsored by the International AIDS Society–USA and funded by the International AIDS Society–USA.
Funding for the live activity, upon which this activity was based came from the following commercial companies:
Major Grants from:
Bristol-Myers Squibb Co.
Substantial Grants from:
Abbott Laboratories
Gilead Sciences
Roche Laboratories/Trimeris
Tibotec Therapeutics
Generous Grants from:
Boehringer Ingelheim Pharmaceuticals, Inc.
GlaxoSmithKline
Additional support for this course was provided by:
Merck and Co., Inc.
Discussion of Investigational or Unapproved Usage
This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the International AIDS Society–USA.
Contact Information
If you have any questions about this Web-based CME conference activity, please contact the International AIDS Society–USA:
International AIDS Society–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2007@iasusa.org
